Literature DB >> 12446926

Hemangiopericytoma in the setting of acromegaly.

W Jeffrey Elias1, Isa M Hussaina, James B Chadduck, John A Jane, Edward R Laws, M Beatriz S Lopes.   

Abstract

Acromegaly is associated with an increased incidence of neoplasia thought to be related in part to tonic increases in circulating levels of insulin-like growth factor-1 (IGF-1). Hemangiopericytomas, particularly those occurring in soft tissues, are known to possess IGF receptors. These tumors often behave aggressively and can be recalcitrant to surgery and radiation therapy. A 49-yr-old man presented with an erosive, midline scalp mass and cutis gyrata. Further diagnostic imaging and endocrinologic analysis confirmed two diagnoses: a hemangiopericytoma and acromegaly associated with an intrasellar pituitary tumor. Both the hemangiopericytoma and the pituitary adenoma were surgically resected; Western blot analysis confirmed the presence of IGF-1 receptors in the hemangiopericytoma. Two years later, the patient underwent resection of a right frontal hemangiopericytoma with an identical histologic phenotype and receptor positivity for IGF-1. The occurrence of a central nervous system hemangiopericytoma in patient with acromegaly is rare. Growth and recurrence of hemangiopericytoma may have been fostered by the presence of IGF-1 receptors. Paracrine mechanisms related to IGF-1 may have contributed to its pathogenesis and growth. The presence of IGF-1 receptors in hemangiopericytomas may have treatment implications for additional adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446926     DOI: 10.1385/ep:13:3:251

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  33 in total

1.  Hemangiopericytoma occurring in the meninges: case report.

Authors:  C F BEGG; R GARRET
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  III. Partial Hypophysectomy for Acromegaly: With Remarks on the Function of the Hypophysis.

Authors:  H Cushing
Journal:  Ann Surg       Date:  1909-12       Impact factor: 12.969

3.  Mechanisms of tumor-induced hypoglycemia with intraabdominal hemangiopericytoma.

Authors:  J Chung; R R Henry
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

4.  Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior.

Authors:  K Thapar; K Kovacs; L Stefaneanu; B Scheithauer; D W Killinger; R V Lioyd; H S Smyth; A Barr; M O Thorner; B Gaylinn; E R Laws
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

5.  Results of surgical treatment for growth hormone-secreting pituitary adenomas.

Authors:  D H Davis; E R Laws; D M Ilstrup; J K Speed; M Caruso; E G Shaw; C F Abboud; B W Scheithauer; L M Root; C Schleck
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

Review 6.  Coexistence of growth hormone-secreting pituitary adenoma and intracranial meningioma: a case report and review of the literature.

Authors:  S Cannavò; L Curtò; R Fazio; S Paterniti; A Blandino; T Marafioti; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

Review 7.  Cutis verticis gyrata: its computed tomographic demonstration in acromegaly.

Authors:  T M Kolawole; I A Al Orainy; P J Patel; S Fathuddin
Journal:  Eur J Radiol       Date:  1998-05       Impact factor: 3.528

8.  Case report: acromegaly and Cushing's disease in a patient with synchronous pituitary adenomas.

Authors:  L S Blevins; G S Hall; D H Madoff; E R Laws; G S Wand
Journal:  Am J Med Sci       Date:  1992-11       Impact factor: 2.378

Review 9.  Colorectal manifestations of endocrine disease.

Authors:  S Sharma; W E Longo; B Baniadam; A M Vernava
Journal:  Dis Colon Rectum       Date:  1995-03       Impact factor: 4.585

10.  An association between acromegaly and thyroid carcinoma.

Authors:  C Balkany; G W Cushing
Journal:  Thyroid       Date:  1995-02       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.